drugset
drugset / Trial / NCT05297994

Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA

NCT05297994 ↗

Phase 2 Completed 400 enrolled St. Petersburg Research Institute of Vaccines and Sera
RandomizedParallel-groupDouble-blindPrevention

Summary

To trial the reactogenicity, safety and immunogenicity of the Flu-M inactivated split influenza vaccine in volunteers aged 18-60 years

Timeline

Start
2016-10-24
Primary completion
2016-12-12
Completion
2017-03-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Flu-M Vaccine 0.5 ml Intramuscular
Comparator Inactivated influenza split vaccine Vaccine 0.5 ml Intramuscular

Indications

influenza